HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.

Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a ​generic version of semaglutide, the active ingredient in ‌Novo Nordisk's blockbuster drug Ozempic, through its platform.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making.

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with.

Hims & Hers, Inc. (HIMS) stock has risen 41% since my last update, driven by product and international expansion. Q1 revenue reached $608 million, up 4% YoY, with U.S. operations declining but international revenue surging 969% to $78 million. The U.S. segment faced tough comps due to prior GLP-1 sales and shipping cadence, while international growth was fueled by ZAVA and Livewell acquisitions.

Raising debt increases the risk in Hims and Hers' stock.

Hims and Hers Health (HIMS) has priced a larger $350 million private offering of 0.00% convertible senior notes due 2032, up from the previously announced $300 mi

Hims & Hers Health Inc (NYSE:HIMS) shares are trading flat during Tuesday's pre-market session as traders continue to digest the company's convertible notes offering.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.

Hims and Hers Health (HIMS, Financials) fell after the company proposed a private offering of $300 million in convertible senior notes due 2032.The company said p